

**Table S1.** Univariate analysis Cox Proportional-Hazards Model of baseline characteristics for a composite endpoint of all-cause death, myocardial infarction, recurrent hospitalization for heart failure, stent thrombosis, or in-stent restenosis


| Variable                           | HR    | 95%CI        | P value |
|------------------------------------|-------|--------------|---------|
| <b>Age</b>                         | 1.06  | 1.01 - 1.11  | 0.01    |
| <b>Sex</b>                         | 0.64  | 0.18 - 2.34  | 0.52    |
| <b>Body Mass index</b>             | 0.92  | 0.83 - 1.01  | 0.09    |
| <b>Diabetes Mellitus</b>           | 0.74  | 0.23 - 2.34  | 0.61    |
| <b>Hypertension</b>                | 1.27  | 0.40 - 3.99  | 0.67    |
| <b>Congestive Heart Failure</b>    | 10.22 | 1.29 - 80.68 | 0.02    |
| <b>Troponin-1</b>                  | 1.18  | 0.71 - 1.97  | 0.51    |
| <b>Previous MI</b>                 | 3.03  | 0.94 - 9.75  | 0.06    |
| <b>Stroke</b>                      | 9.20  | 1.94 - 43.43 | 0.005   |
| <b>Chronic Kidney Disease</b>      | 1.08  | 0 - Inf      | 0.99    |
| <b>Peripheral vascular disease</b> | 3.98  | 0.51 - 30.71 | 0.18    |

HR, hazardous ratio; CI, confidence interval; MI, myocardial infarction.

**Table S2.** Univariate analysis Cox Proportional-Hazards Model of inflammatory cells for a composite endpoint of all-cause death, myocardial infarction, recurrent hospitalization for heart failure, stent thrombosis, or in-stent restenosis

| Variable                     | HR   | 95%CI        | P value |
|------------------------------|------|--------------|---------|
| <b>CD14+/HLA-DR+</b>         | 3.80 | 1.19 - 12.13 | 0.02    |
| <b>CD14+CD16– Monocytes</b>  | 0.94 | 0.32 - 2.71  | 0.91    |
| <b>CD14+CD16–/CCR2+</b>      | 0.67 | 0.22 - 2.00  | 0.47    |
| <b>CD14+CD16–/CD11b+</b>     | 1.94 | 0.65- 5.79   | 0.23    |
| <b>CD14+CD16–/CD42b+</b>     | 1.44 | 0.51 - 4.03  | 0.48    |
| <b>CD14++CD16+ Monocytes</b> | 1.28 | 0.45 - 3.68  | 0.63    |
| <b>CD14++CD16+/ CCR2+</b>    | 1.24 | 0.44 - 3.48  | 0.68    |
| <b>CD14++CD16+/ CD11b+</b>   | 0.62 | 0.20 - 1.84  | 0.39    |
| <b>CD14++CD16+/ CD42b+</b>   | 1.61 | 0.57 - 4.54  | 0.36    |
| <b>CD14+CD16++ Monocytes</b> | 3.48 | 1.08 - 11.26 | 0.03    |
| <b>CD14+CD16++/ CCR2+</b>    | 2.73 | 0.91 - 8.11  | 0.07    |
| <b>CD14+CD16++/ CD11b+</b>   | 4.99 | 1.46 - 7.06  | 0.01    |
| <b>CD14+CD16++/ CD42b+</b>   | 2.86 | 0.95 - 8.55  | 0.05    |

HR, hazardous ratio; CI, confidence interval.



**Figure S1.** Flow cytometry gating strategy demonstrating the gating method for monocytes and their classification into classical, intermediate, and non-classical monocytes.